Proof-point cadence: the last promised marker just landed, and the next one is already on the clock
The model's full reasoning — Q3 2018 call → NOWe need to determine if management presents a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near. Let's analyze the transcript. Management (Gary Maharaj and Tim Arens) discuss several strategic objectives. They mention: - Transcend clinical trial for SurVeil: "progressed nicely throughout the quarter. We're well on our way to having all U.S. clinical sites initiated by the end of fiscal 2018 as planned." That's a future milestone, not yet delivered. They also say "We expect to complete transcend enrollment by the end of fiscal 2019." That's a next marker, but it's not near-term (fiscal 2019 is about a year away). Also, they say "We continue to expect a filing for the first human used for below the knee and AV fistula access drug-coated balloon in fiscal 2018." That's a near-term marker (fiscal 2018 ends soon). But is that a marker just delivered? No, it's expected in the future. They also say "We're making progress with our 014 sirolimus coated balloons for below the knee drug-coated balloons. And we're currently working through the preclinical studies for the data package that will be used to determine our readiness for first in human trial. We remain on track for this program and expect to make continued progress throughout the remainder of fiscal 2008." That's vague. - They mention the Embolitech acquisition: "we announced acquisition of an innovated from thrombectomy platform technology and the related intellectual property from Embolitech." That was in May, so it's a completed acquisition. But is that a "marker just delivered"? It's a completed acquisition, but it's not a checkpoint on a path they had described? They say "We will use our design and development capabilities... as we absorb this technology into our whole product solution pipeline." They also say "we are currently executing in a very aggressive timeline with expectations to submit our first application for regulatory approval in the first half of calendar 2020." That's a next marker, but it's more than a year away (calendar 2020 is about 1.5 years away). Also, they say "we are already working on an initial prototypes and test methods" - that's ongoing, not a specific checkpoint. - They mention product launches: "we recently launched the MatrixGuard Diluent" - that's a product launch, a concrete step.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | Q3 2023 | 2023-11-04 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.